Thanks irenekwshiu, I'm excited about the adult trial - just need the "second potency assay signed off".
What was frustrating is that shareholders were not informed we were part of an EAP in the first place. We get told we are double the survival percentage of the only approved product as an aside. Marketing is not our CEO's strong suit
Reg
Ann: Half Year Financial Results Presentation, page-66
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.03 |
Change
0.005(0.49%) |
Mkt cap ! $1.170B | |||
| Open | High | Low | Value | Volume |
| $1.02 | $1.04 | $1.02 | $1.350M | 1.315M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 16 | 191566 | $1.02 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.03 | 50485 | 17 |
View Market Depth
| Last trade - 12.05pm 01/08/2024 (20 minute delay) ? |
| MSB (ASX) Chart |